EVOK Relative Valuation
EVOK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EVOK is overvalued; if below, it's undervalued.
Historical Valuation
Evoke Pharma Inc (EVOK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 2.85. The fair price of Evoke Pharma Inc (EVOK) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 10.94 USD , Evoke Pharma Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：10.94
Fair
Undervalued
273.50
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Evoke Pharma Inc. (EVOK) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.08. The thresholds are as follows: Strongly Undervalued below -0.53, Undervalued between -0.53 and -0.22, Fairly Valued between 0.38 and -0.22, Overvalued between 0.38 and 0.69, and Strongly Overvalued above 0.69. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
45.10
EV/EBIT
Evoke Pharma Inc. (EVOK) has a current EV/EBIT of 45.10. The 5-year average EV/EBIT is 0.19. The thresholds are as follows: Strongly Undervalued below -14.39, Undervalued between -14.39 and -7.10, Fairly Valued between 7.48 and -7.10, Overvalued between 7.48 and 14.77, and Strongly Overvalued above 14.77. The current Forward EV/EBIT of 45.10 falls within the Strongly Overvalued range.
1.03
PS
Evoke Pharma Inc. (EVOK) has a current PS of 1.03. The 5-year average PS is 5.24. The thresholds are as follows: Strongly Undervalued below -17.16, Undervalued between -17.16 and -5.96, Fairly Valued between 16.44 and -5.96, Overvalued between 16.44 and 27.64, and Strongly Overvalued above 27.64. The current Forward PS of 1.03 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Evoke Pharma Inc. (EVOK) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.13. The thresholds are as follows: Strongly Undervalued below -0.75, Undervalued between -0.75 and -0.31, Fairly Valued between 0.57 and -0.31, Overvalued between 0.57 and 1.00, and Strongly Overvalued above 1.00. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Evoke Pharma Inc. (EVOK) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.13. The thresholds are as follows: Strongly Undervalued below -0.75, Undervalued between -0.75 and -0.31, Fairly Valued between 0.57 and -0.31, Overvalued between 0.57 and 1.00, and Strongly Overvalued above 1.00. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Evoke Pharma Inc (EVOK) has a current Price-to-Book (P/B) ratio of 7.02. Compared to its 3-year average P/B ratio of 1.74 , the current P/B ratio is approximately 302.10% higher. Relative to its 5-year average P/B ratio of 0.97, the current P/B ratio is about 625.36% higher. Evoke Pharma Inc (EVOK) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -101.72%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -83.57% , the current FCF yield is about -100.00% lower.
7.02
P/B
Median3y
1.74
Median5y
0.97
-14.11
FCF Yield
Median3y
-101.72
Median5y
-83.57
Competitors Valuation Multiple
The average P/S ratio for EVOK's competitors is 1.02, providing a benchmark for relative valuation. Evoke Pharma Inc Corp (EVOK) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 61.40%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of EVOK increased by 147.51% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.52 to -5.83.
The secondary factor is the Revenue Growth, contributed 61.40%to the performance.
Overall, the performance of EVOK in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Evoke Pharma Inc (EVOK) currently overvalued or undervalued?
What is Evoke Pharma Inc (EVOK) fair value?
How does EVOK's valuation metrics compare to the industry average?
What is the current P/B ratio for Evoke Pharma Inc (EVOK) as of Dec 05 2025?
What is the current FCF Yield for Evoke Pharma Inc (EVOK) as of Dec 05 2025?
What is the current Forward P/E ratio for Evoke Pharma Inc (EVOK) as of Dec 05 2025?